论文部分内容阅读
口服卡托普利(Captopril,巯甲丙脯酸)治疗心脏病患者31例,疗程3个月。治疗前后用二维超声心动图测量出室间隔厚度、左心室后盛厚度和左室舒张末期内径,并计算出左室重量(LVM)。发现治疗后LVM较治疗前平均减轻17.2％(233.90±61.36 VS 193.68±33.96,P<0.05),而对照组治疗前后无显著差异(P>0.05)。X线心脏远达摄片测得的心胸比率亦有相应变化(0.60±0.16 VS 0.52±0.08,P<0.01)。故认为卡托普利治疗心脏增大的心脏病是可选用的药物。其作用机理可能是多方面的。
Thirty-one patients were treated with captopril (captopril) for 3 months. The ventricular septal thickness, posterior systolic thickness, and left ventricular end-diastolic diameter were measured by two-dimensional echocardiography before and after treatment, and left ventricular mass (LVM) was calculated. It was found that LVM decreased by 17.2% (233.90 ± 61.36 vs 193.68 ± 33.96, P <0.05) before treatment, while no significant difference was found in the control group before and after treatment (P> 0.05). The ratio of cardiothoracic to chest radiograph measured by X-ray imaging also changed accordingly (0.60 ± 0.16 vs 0.52 ± 0.08, P <0.01). Therefore, captopril treatment of heart disease is an optional heart disease. Its mechanism of action may be multifaceted.